PE20060185A1 - ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA - Google Patents

ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA

Info

Publication number
PE20060185A1
PE20060185A1 PE2005000428A PE2005000428A PE20060185A1 PE 20060185 A1 PE20060185 A1 PE 20060185A1 PE 2005000428 A PE2005000428 A PE 2005000428A PE 2005000428 A PE2005000428 A PE 2005000428A PE 20060185 A1 PE20060185 A1 PE 20060185A1
Authority
PE
Peru
Prior art keywords
adenosine
triazolo
pyrimidine
receptor antagonist
alcoxyalkyl
Prior art date
Application number
PE2005000428A
Other languages
English (en)
Inventor
Bernard R Neustadt
Jinsong Hao
Hong Liu
Samuel Chackalamannil
Andrew Stamford
Joel M Harris
Unmesh G Shah
Craig D Boyle
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060185(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20060185A1 publication Critical patent/PE20060185A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R ES R6-FENILO, R6-TIENILO, CICLOALQUENILO, ENTRE OTROS; R1, R2, R3, R4 Y R5 SON CADA UNO H, ALQUILO, ALCOXIALQUILO; R6 ES UNO A 3 SUSTITUYENTES SELECCIONADOS DE H, ALQUILO, -CF3, HALOGENO, -NO2, -CN, ALCOXI, ENTRE OTROS; Z ES ALQUENILO, ALCOXIALQUILO, R10-HETEROARILO, ENTRE OTROS; R10 ES 1-3 SUSTITUYENTES SELECCIONADOS ENTRE H, ALQUILO, HIDROXI, ALCOXIALQUILO, HIDROXIALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: A, B, ENTRE OTROS. SE REFIERE TAMBIEN A UN COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON ANTAGONISTAS DEL RECEPTOR A2a DE ADENOSINA UTILES EN EL TRATAMIENTO DE PARKINSON
PE2005000428A 2004-04-21 2005-04-19 ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA PE20060185A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56391304P 2004-04-21 2004-04-21
US60996604P 2004-09-15 2004-09-15

Publications (1)

Publication Number Publication Date
PE20060185A1 true PE20060185A1 (es) 2006-03-20

Family

ID=34966464

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000428A PE20060185A1 (es) 2004-04-21 2005-04-19 ANTAGONISTA DEL RECEPTOR A2A DE LA ADENOSINA CON ESTRUCTURA DE PIRAZOLO--[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIMIDINA

Country Status (16)

Country Link
US (1) US7709492B2 (es)
EP (1) EP1745047B1 (es)
JP (2) JP2007533754A (es)
KR (1) KR20060135901A (es)
AR (1) AR048617A1 (es)
AT (1) ATE461932T1 (es)
AU (1) AU2005236059B2 (es)
CA (1) CA2563635A1 (es)
DE (1) DE602005020127D1 (es)
ES (1) ES2342082T3 (es)
IL (1) IL178674A0 (es)
MX (1) MXPA06012231A (es)
NZ (1) NZ550591A (es)
PE (1) PE20060185A1 (es)
TW (1) TW200538118A (es)
WO (1) WO2005103055A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1283839T1 (es) * 2000-05-26 2005-08-31 Schering Corp
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP2100877B1 (en) 2003-09-19 2012-01-25 Janssen Pharmaceutica N.V. 4-((Phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
US20080119477A1 (en) * 2004-12-13 2008-05-22 Smith Brian M N-Biaryl and N-Arylheteroaryl Piperazine Derivatives as Modulators of the 5Ht2c Receptor Useful For the Treatment of Disorders Related Thereto
TW200633721A (en) * 2004-12-14 2006-10-01 Shionogi & Co A pharmaceutical composition for treating constipation
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2622741A1 (en) 2005-09-19 2007-03-29 Schering Corporation 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
UY30288A1 (es) 2006-04-18 2007-08-31 Janssen Pharmaceutica Nv Derivados del ácido benzoazepin-oxi-acético como agonistas de ppar-delta usados para aumentar hdl-c. reducir ldl-c y reducir colesterol
US7691869B2 (en) * 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
AU2009222047A1 (en) * 2008-03-04 2009-09-11 Schering Corporation 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists
WO2010068756A2 (en) 2008-12-10 2010-06-17 Thesis Chemistry, Llc Process for manufacture of optically active 2-(acyloxymethyl)-1, 3 oxathiolanes
EP2379556A1 (en) * 2008-12-30 2011-10-26 ArQule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US8431699B2 (en) * 2009-02-27 2013-04-30 Vertichem Corporation Method for manufacture of 2-oxoimidazolidines
WO2010104194A1 (en) * 2009-03-10 2010-09-16 Takeda Pharmaceutical Company Limited Benzofuran derivatives
WO2010114894A1 (en) * 2009-03-31 2010-10-07 Arqule, Inc. Substituted heterocyclic compounds
BR112012007635B1 (pt) * 2009-10-08 2019-07-09 Sanofi Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação
JP5843869B2 (ja) * 2010-09-24 2016-01-13 アドヴィナス・セラピューティックス・リミテッド アデノシン受容体拮抗薬としての縮合三環化合物
WO2012135084A1 (en) * 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS
KR101795562B1 (ko) * 2011-12-27 2017-11-08 (주)바이오팜솔루션즈 뇌졸중의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
CN115873022A (zh) * 2017-03-30 2023-03-31 伊忒欧斯比利时股份公司 作为a2a抑制剂的2-氧代噻唑衍生物和用于治疗癌症的化合物
WO2018178338A1 (en) * 2017-03-30 2018-10-04 Iteos Therapeutics 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
CN108218796A (zh) * 2017-12-31 2018-06-29 佛山市赛维斯医药科技有限公司 含酰肼结构的化合物、制备方法及其用途
CN107935953A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含末端烯键和酰肼结构的comt抑制剂、制备方法及其用途
CN108191775A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种末端烯丙基丙酰肼结构化合物及其用途
CN108148004A (zh) * 2017-12-31 2018-06-12 佛山市赛维斯医药科技有限公司 一种含丙酰肼和嘧啶结构的化合物、制备方法及其用途
JP2021520392A (ja) 2018-04-08 2021-08-19 ベイジーン リミテッド Ａ２ａ受容体アンタゴニストとしてのピラゾロトリアゾロピリミジン誘導体
CN110742893B (zh) * 2018-07-23 2024-04-05 百济神州(北京)生物科技有限公司 A2a受体拮抗剂治疗癌症的方法
US11376255B2 (en) 2018-09-11 2022-07-05 iTeos Belgium SA Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents
BE1026758B1 (fr) * 2018-09-11 2020-06-09 Iteos Therapeutics S A Composition pharmaceutique comprenant des dérivés de thiocarbamate inhibiteurs d’a2a
MX2021002865A (es) * 2018-09-11 2021-07-16 iTeos Belgium SA Derivados de tiocarbamato como inhibidores de a2a, composición farmacéutica de los mismos y combinaciones con agentes antineoplásicos.
BE1026615B1 (fr) * 2018-09-27 2020-07-06 Iteos Therapeutics S A Combinaison d’un inhibiteur du récepteur a2a et d'un agent anticancéreux
BE1026602B1 (fr) * 2018-09-27 2020-06-18 Iteos Therapeutics S A Inhibiteurs d’a2a ne penetrant pas dans le cerveau et methodes d’utilisation dans le traitement de cancers
US11427594B2 (en) 2018-09-27 2022-08-30 iTeos Belgium SA Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers
WO2020106558A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
WO2020106560A1 (en) 2018-11-20 2020-05-28 Merck Sharp & Dohme Corp. Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use
CR20210271A (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
JP2022511778A (ja) 2018-11-30 2022-02-01 メルク・シャープ・アンド・ドーム・コーポレーション アデノシン受容体拮抗薬としての７－、８－及び１０－置換されたアミノトリアゾロキナゾリン誘導体、医薬組成物及びそれらの使用
WO2020227156A1 (en) * 2019-05-03 2020-11-12 Nektar Therapeutics Adenosine 2 receptor antagonists
CN114667287A (zh) * 2019-07-17 2022-06-24 泰昂治疗公司 腺苷a2a受体拮抗剂及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
ATE208199T1 (de) 1993-07-27 2001-11-15 Kyowa Hakko Kogyo Kk Arzneimittel gegen parkinsonsche krankheit
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
SI1283839T1 (es) * 2000-05-26 2005-08-31 Schering Corp
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
AR037243A1 (es) * 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
AU2003304527B2 (en) 2002-12-19 2010-09-09 Merck Sharp & Dohme Corp. Uses of adenosine A2a receptor antagonists
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
ATE461932T1 (de) 2010-04-15
IL178674A0 (en) 2007-02-11
JP2008231111A (ja) 2008-10-02
MXPA06012231A (es) 2006-12-15
JP2007533754A (ja) 2007-11-22
TW200538118A (en) 2005-12-01
DE602005020127D1 (de) 2010-05-06
AU2005236059B2 (en) 2009-01-15
ES2342082T3 (es) 2010-07-01
HK1095818A1 (en) 2007-05-18
AU2005236059A1 (en) 2005-11-03
NZ550591A (en) 2010-10-29
CA2563635A1 (en) 2005-11-03
US20050239795A1 (en) 2005-10-27
KR20060135901A (ko) 2006-12-29
AR048617A1 (es) 2006-05-10
WO2005103055A1 (en) 2005-11-03
EP1745047A1 (en) 2007-01-24
US7709492B2 (en) 2010-05-04
EP1745047B1 (en) 2010-03-24

Similar Documents

Publication Publication Date Title
AR037243A1 (es) Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
ES2974334T3 (es) Inhibidores heterocíclicos de ATR cinasa
PE20090960A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas
PE20091068A1 (es) Compuestos pirrolo[3,2-d]pirimidina y su uso como inhibidores de quinasa pi3 y quinasa mtor
PE20070752A1 (es) Triazolopiridazinas como moduladores de quinasa
PE20120224A1 (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
CY1109263T1 (el) Ανταγωνιστες των α2α υποδοχεων αδενοσινης 2-alkynyl-kai 2-αλκενυλ-pyrazolo-[4,3-ε]-1,2,4-triazolo-[1,5-c]-pyrimidine
CO5700778A2 (es) Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
PE20081888A1 (es) ANALOGOS DE PIRAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE CINASA mTOR Y CINASA PI3
PE20190509A1 (es) 3-oxo-2,6-difenil-2,3-dihidropiridazin-4-carboxamidas
PE20090674A1 (es) Compuestos multiciclicos
PE20010736A1 (es) PIRAZOL-[4,3-d]-PIRIMIDIN-7-ONA COMO INHIBIDORES DE LA 3`,5'-GUANOSINMONOFOSFATO CICLICO FOSFODIESTERASA
PE20060604A1 (es) Derivados del tetrahidronaftaleno como agentes antiinflamatorios y procedimiento para su preparacion
PE20170003A1 (es) Compuestos heterociclicos y usos de los mismos
HUP0401047A2 (hu) Triazolo[4,5-d]pirimidin-származékok, alkalmazásuk purinergikus receptor-antagonistákként és a vegyületet tartalmazó gyógyszerkészítmények
PE20090370A1 (es) Derivados de heterociclo fusionado como inhibidores de quinasa
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
HUP0402324A2 (hu) [1,2,4]-Triazolo[1,5-a]piridin- és [1,2,4]triazolo[1,5-c]pirimidin-származékok mint adenozin A2a receptor antagonisták és az ezeket tartalmazó gyógyszerkészítmények
PE20110560A1 (es) NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
PE20121443A1 (es) Derivados de etinilo
WO2006068954A3 (en) PYRAZOLO[1,5-A]PYRIMIDINE ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20180116A1 (es) HETEROCICLILMETIL-TIENOURACILO COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2b
PE20091083A1 (es) Moduladores tieno- y furo- pirimidina del receptor de histamina h4
WO2012020215A1 (en) Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed